Abbott (ABT) Q3 2023: Base Business Grows 14% as Freestyle Libre Surges, Margin Expansion in Focus
Abbott’s core business delivered another quarter of accelerating double-digit growth, led by Freestyle Libre and a full recovery in Nutrition, while leadership signaled confidence in sustaining high-single-digit sales and double-digit EPS growth into 2024. Margin expansion and product mix shifts are set to drive the next leg of earnings power, with management emphasizing operational resilience and pipeline execution amid macro and China policy headwinds. Investors should watch for gross margin recovery and continued momentum in high-growth segments as key levers for valuation upside.
Summary
- Freestyle Libre and Nutrition Recovery: Diabetes and nutrition outperformed, fueling core growth and market share gains.
- Margin Levers Identified: Product mix, easing commodity costs, and operational discipline set up gross margin expansion.
- 2024 Growth Framework Reinforced: Leadership projects sustained top-line acceleration and robust pipeline execution into next year.
Business Overview
Abbott Laboratories is a diversified global healthcare company generating revenue through four primary segments: medical devices, diagnostics, nutrition, and established pharmaceuticals. The company’s business model blends recurring revenue from consumables and devices with branded nutritionals and pharmaceuticals, with recent growth driven by diabetes care (Freestyle Libre, continuous glucose monitor), cardiovascular devices, and a rebound in U.S. infant formula. Key segments include Nutrition (pediatric and adult brands), Diagnostics (CoreLab, rapid tests), Medical Devices (diabetes, cardiovascular, neuromodulation), and Established Pharmaceuticals (branded generics in emerging markets).
Performance Analysis
Abbott’s Q3 2023 results underscore a decisive pivot away from COVID testing dependency, with the base business (excluding COVID) growing nearly 14% organically. All four major segments posted double-digit organic sales growth, a rare feat in diversified healthcare. Nutrition led at 18% growth, driven by U.S. infant formula share gains and robust international performance, while adult nutrition also outpaced expectations on Ensure and Glucerna demand. Diabetes care was a standout, with Freestyle Libre up 28%, now exceeding 5 million global users, and showing accelerating adoption in the U.S. and internationally, including strong tailwinds from expanded reimbursement for Type 2 basal insulin users.
Diagnostics rebounded with 10% organic growth (ex-COVID), as routine and blood transfusion testing volumes recovered, and rapid diagnostics saw above-seasonal demand. Medical devices delivered nearly 15% growth, with cardiovascular and neuromodulation launches (notably Eterna for pain management) gaining traction. Gross margin, at 55% YTD, trailed original guidance, pressured by lower COVID test volumes, price, and inventory obsolescence, but management expects normalization as supply chains stabilize and product mix improves.
- Diabetes Momentum Accelerates: Freestyle Libre’s growth is now supported by complementary GLP-1 therapy use, driving higher compliance and user engagement.
- Nutrition Market Share Reclaimed: Abbott regained U.S. infant formula leadership, approaching 90% of pre-recall share, with sequential monthly gains.
- Diagnostics and Devices Diversify Growth: CoreLab and cardiovascular devices both outgrew market rates, offsetting price headwinds in China and providing resilience.
FX remained a modest headwind, and management flagged ongoing gross margin pressure from legacy inventory and lower COVID test pricing, but signaled a tailwind from easing commodity and freight costs as a lever for 2024 profitability.
Executive Commentary
"Organic sales growth on the base business, which excludes COVID testing, increased double digits for the third consecutive quarter and was led by double digit growth in all four of our major businesses. This acceleration in sales growth is a result of our strong position in attractive growth markets in conjunction with the additional investments we made across the company during the pandemic."
Robert Ford, Chairman and Chief Executive Officer
"The adjusted gross margin ratio was 55% of sales. The difference is primarily due to lower gross margins on COVID tests due to lower volumes and price compared to our original forecast assumptions and the impact of higher inventory obsolescence as a result of maintaining higher inventory levels throughout the pandemic to help ensure product supply during a time when global supply chains were less predictable."
Phil Boudreau, Senior Vice President Finance and Chief Financial Officer
Strategic Positioning
1. Diabetes Ecosystem Expansion
Freestyle Libre’s continued rapid adoption, now with over 5 million users, reflects not just product leadership but also Abbott’s ability to leverage real-world data and adjacent therapy trends (GLP-1 drugs, glucose-lowering medications). Management is actively using its 50 billion+ hours of glucose data to deepen engagement and explore new clinical and commercial opportunities, including integration with pumps and new analytes (Lingo, metabolic biosensor platform).
2. Nutrition Leadership and Channel Recovery
Abbott’s U.S. infant formula business has nearly regained pre-recall market share, a testament to supply chain restoration and targeted demand generation. The company’s channel strategy—prioritizing underserved WIC (Women, Infants, and Children program) and expanding non-WIC share—has supported a durable rebound. Adult nutrition brands continue to benefit from demographic and health trends globally.
3. Diversification in Diagnostics and Devices
Diagnostics returned to growth, with CoreLab and rapid tests both outpacing market recovery. Abbott’s medical device portfolio is broadening with new launches (Eterna, leadless pacemakers, TAVR valves), and the company is actively managing China pricing headwinds (VBP, volume-based procurement) by leveraging share gains and incremental volume opportunities in affected categories.
4. Margin Expansion Playbook
Gross margin recovery is a central lever for 2024, driven by easing commodity costs, normalized supply chains, and a richer mix of high-margin products. Leadership is focused on operational cost discipline, optimizing freight modalities, and scaling new launches to offset lingering COVID-related headwinds.
5. Pipeline and M&A as Growth Multipliers
Abbott’s recent acquisitions (CSI in vascular, Bigfoot for diabetes, MabScience biosimilars) and pipeline momentum (Triclip, Lingo, expanded Libre coverage) reflect a deliberate strategy to add scale and innovation in core and adjacent markets. Management remains active on M&A, emphasizing strategic fit and value-add potential, with capacity for further deals if valuations align.
Key Considerations
This quarter’s results reinforce Abbott’s high-growth narrative, but investors must weigh several evolving dynamics as the company enters a new phase of post-pandemic normalization and margin rebuilding.
Key Considerations:
- Product Mix Shift: Higher-growth, higher-margin segments (Libre, structural heart, neuromodulation) are now a larger share of sales, improving margin trajectory.
- China Policy Impact: Volume-based procurement (VBP) and anti-corruption initiatives in China are being managed, but will pressure pricing in diagnostics and devices; Abbott is offsetting with share and volume gains.
- GLP-1 Therapy Integration: Complementarity between Libre and GLP-1 drugs is driving higher compliance, but long-term MedTech market impact remains a sector-wide debate.
- Gross Margin Recovery Pace: Margin expansion depends on cost tailwinds and scaling of new products; visibility is improving but full normalization to pre-COVID levels may take time.
- Pipeline Execution Risk: Timely commercialization of Triclip, Lingo, and other launches will be key to sustaining above-market growth rates.
Risks
Key risks include potential for slower-than-expected margin recovery, especially if commodity or freight costs reverse, or if China pricing actions intensify. Pipeline execution delays, particularly in high-profile launches (Triclip, Lingo), could disrupt growth cadence. Macroeconomic uncertainty, currency headwinds, and competitive intensity in devices and diagnostics also pose downside risk to both top-line and earnings targets. Management’s confidence is high, but investors should monitor for signs of delayed gross margin improvement or pipeline slippage.
Forward Outlook
For Q4 2023, Abbott guided to:
- Low double-digit organic sales growth in the base business (excluding COVID testing)
- Ongoing EPS of $1.17 to $1.21
For full-year 2023, management raised and narrowed adjusted EPS guidance to:
- $4.42 to $4.46
Management highlighted several factors that will shape the outlook:
- Gross margin tailwinds from lower commodity and freight costs, and improved product mix
- Continued double-digit growth in base business segments, led by diabetes and nutrition
Takeaways
Abbott’s Q3 confirms the base business is now the primary growth driver, with COVID testing no longer masking underlying momentum. The company’s ability to deliver double-digit sales and earnings growth across all major segments, while executing on share gains and pipeline launches, supports the sustainability of its growth framework.
- Base Business Delivers: Double-digit growth across all segments, led by Freestyle Libre and nutrition, supports a durable high-single-digit growth thesis.
- Margin Levers in Play: Gross margin recovery is underway, with commodity and freight cost normalization and product mix improvement poised to accelerate earnings power.
- 2024 Setup: Investors should watch for execution on new launches and margin expansion as Abbott aims to deliver on its high-single-digit sales and double-digit EPS growth framework into next year.
Conclusion
Abbott’s Q3 marks a clear inflection in its post-pandemic trajectory, as the company leans on high-growth franchises and operational discipline to drive both top-line and margin expansion. While risks remain, the broad-based acceleration and pipeline execution position Abbott as a leader among diversified healthcare peers heading into 2024.
Industry Read-Through
Abbott’s results reinforce several sector-wide themes: demand for chronic disease management tools (especially CGM and diabetes), the importance of supply chain normalization for margin recovery, and the resilience of diversified healthcare models in navigating macro and policy headwinds. The complementary dynamic between digital health devices and pharmaceutical therapies (GLP-1s and CGM) is likely to shape future MedTech and pharma strategies, with data-driven platforms emerging as competitive differentiators. China’s VBP and regulatory environment remain a watchpoint for all multinational device and diagnostics companies, as price-volume tradeoffs become a standard feature in emerging markets. Margin expansion via product mix and cost discipline will be a key investor focus across the sector in 2024.